Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960102 | 0.92 | GSK3B (0.33) | GSK3BGSK3ACHRM4CDK1 | |
| SCHEMBL1960159 | 0.91 | GSK3B (0.39) | GSK3BGSK3ACHRM4CDK1 | |
| SCHEMBL1120237 | 0.90 | GSK3B (0.34) | GSK3BGSK3ACDK1 | |
| SCHEMBL1119573 | 0.90 | DPP4 (0.36) | GSK3BGSK3ACDK1 | |
| SCHEMBL7993037 | 0.88 | CCR4 (0.34) | GSK3BGSK3ACHRM4 | |
| SCHEMBL1964817 | 0.87 | GSK3B (0.33) | GSK3BGSK3ACHRM4 | |
| SCHEMBL16474803 | 0.86 | CHRM4 (0.32) | GSK3BGSK3ACHRM4 | |
| SCHEMBL8003491 | 0.85 | GSK3B (0.32) | GSK3BGSK3A | |
| SCHEMBL1965614 | 0.85 | NOS3 (0.38) | GSK3BGSK3A | |
| SCHEMBL1119497 | 0.84 | MAPK14 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2280976-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009138176-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138176-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | GSK3B 3829/4885GSK3A 3600/4885CHRM4 3840/4885 |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | GSK3B 3829/4885GSK3A 3600/4885CHRM4 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.